Aripiprazole once-monthly for the treatment of adult patients with earlier-stage bipolar I disorder: a post hoc analysis of data from a double-blind, placebo-controlled, 52-week randomized withdrawal trial
In this post hoc analysis, AOM 400 prolonged time to recurrence of any mood episode versus placebo in earlier-stage BP-I. These findings support early initiation of maintenance treatment with AOM 400.
Authors
- Mauricio Tohen (ORCID: https://orcid.org/0000-0001-8049-4351)
- Karimah S. Bell Lynum (ORCID: https://orcid.org/0000-0002-2045-9578)
- Carmen Castro (ORCID: https://orcid.org/0000-0002-6802-0572)
- Mehul Patel (ORCID: https://orcid.org/0000-0002-5681-5888)
- Zhen Zhang (ORCID: https://orcid.org/0000-0001-8448-5663)
Institutions
- University of New Mexico (US)
- Otsuka (United States) (US)
- Deerfield (United States) (US)
- Otsuka Pharmaceutical (Spain) (ES)
- Lundbeck (United States) (US)
Publication Details
- Journal
- International Journal of Bipolar Disorders
- Published
- 2024-10-27
- DOI
- https://doi.org/10.1186/s40345-024-00358-3
- Citations
- 2
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- Otsuka Pharmaceutical
- H. Lundbeck A/S
- Otsuka Pharmaceutical Development and Commercialization